HCPCS J7170 is officially defined as "Injection, emicizumab-kxwh, 0.5 mg." HCPCS J7170 is referenced in 7 tracked payer policy changes from Florida Blue, Humana, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7170 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Florida Blue Medicare updated its Part B Step Therapy program effective May 15, 2026, adding new non-preferred drugs and changing preferred status for medications in Asthma, Cancer, and Hemophilia categories. Providers must try preferred alternatives before prescribing non-preferred drugs or face coverage denials.
This is a historical policy document (issued 2026-01-01, discovered 2026-10-06) establishing Humana Medicaid Ohio's IVIG (immune globulin) prior authorization requirements across 25 product formulations and 24 clinical indications. The policy specifies preferred products, step-therapy rules, and approval criteria for conditions ranging from primary immunodeficiency to autoimmune diseases. Since this policy became effective on 2026-01-01 and is now 9 months past implementation, verify current applicability with Humana before applying these requirements.
Independence Blue Cross updated policy 08.00.92ak effective 01/01/2026 to add coverage for two new coagulation factor products: Concizumab-mtci (Alhemo) and Fitusiran (Qfitlia) for hemophilia A and B treatment with or without inhibitors. One new HCPCS code (J7174) was added for fitusiran; Concizumab-mtci uses existing unclassified drug codes (C9399, J3590). All ICD-10 diagnosis codes were removed from the policy—providers must report the most appropriate diagnosis code supporting medical necessity.
Independence Blue Cross Medicare Advantage updated policy MA08.004z effective 01/01/2026 to add coverage for two new hemophilia treatment products: Concizumab-mtci (Alhemo) and Fitusiran (Qfitlia). The policy adds HCPCS code J7174 for fitusiran and clarifies that Concizumab-mtci uses unclassified drug codes (C9399, J3590). All ICD-10 diagnosis codes have been removed from the policy; providers must now report the most appropriate diagnosis code based on medical necessity criteria.
Aetna's clotting factor policy applies to commercial medical plans, and the Medicare criteria are set out separately in the Medicare Part B Criteria. Precertification of clotting factors is required of all Aetna participating providers and members in applicable plan designs, and it is requested through Aetna's Special Case Precertification Unit at (855) 888-9046. Clotting factor products must be prescribed by or in consultation with a hematologist, and Aetna considers all other indications experimental, investigational, or unproven.
Coverage for hemophilia therapy for immediate treatment may be considered medically necessary when all criteria are met: the individual has hemophilia A, hemophilia B, factor X deficiency or von Willebrand disease, is currently bleeding, is out of medication and needs immediate use, and has no FDA labeled contraindication to the requested agent. Esperoct, Hympavzi, Jivi, Qfitlia (fitusiran) and Roctavian are considered not medically necessary because other alternatives are covered by the plan for the treatment of Hemophilia A and Hemophilia B. The policy history dates the update that added Qfitlia to that list to 11/01/2025.
Effective January 1, 2019, Tisagenlecleucel code Q2042 and breast MRI codes 77046, 77047, 77048 and 77049 are now reviewed by AIM Specialty Health and require prior authorization, and A9584 (iodine I-123 ioflupane) is now reviewed for medical necessity and requires prior authorization. Breast MRI codes 77058 and 77059 are no longer reviewed by AIM Specialty Health, and the CAR-T codes 0537T through 0540T are listed as not reviewed and noncovered. Effective January 4, 2019, a long list of genetic testing codes beginning with 81120 and 81121 is now reviewed by AIM Specialty Health and requires prior authorization.
Watch J7170
Get one email when a payer policy names J7170, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J7170
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J7170 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.